21
OCT
2016

NW BIO Announces Registered Direct Offering

Posted By :
Comments : Off
BETHESDA, Md., October 21, 2016 – Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has entered into a definitive agreement with an institutional investor for a registered direct offering with gross proceeds of approximately $5million. The proceeds will be used in connection with upcoming Phase II clinical trials....
Read More
29
SEP
2016

NW Bio Presents Further DCVax®-Direct Phase I Trial Information On Individual Patient Survival At NY Cancer Immunotherapy Conference

Posted By :
Comments : Off
BETHESDA, MD, September 29, 2016 – Northwest Biotherapeutics (NASDAQ: NWBO) (“NW Bio”), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that Dr. Marnix Bosch, Chief Technical Officer of NW Bio, presented additional information relating to the DCVax®-Direct Phase I Trial in a poster presentation at the Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference:...
Read More
21
SEP
2016

NW Bio Presents Updated Data From DCVax®-Direct Phase I Trial At 5th Annual SMi Cancer Vaccines Conference in London

Posted By :
Comments : Off
Dr. Marnix Bosch, Chief Technical Officer, Presented   BETHESDA, MD, September 21, 2016 – Northwest Biotherapeutics (NASDAQ: NWBO) (“NW Bio”), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that Dr. Marnix Bosch, Chief Technical Officer, today presented an updated and more detailed analysis of the Phase I DCVax®-Direct Trial data at the 5th Annual SMi Cancer Vaccines...
Read More
06
SEP
2016

NASDAQ Accepts NW Bio Remediation Plan For Shares and Warrants Previously Issued to Cognate BioServices

Posted By :
Comments : Off
Shares and Warrants To Be Cancelled and Reduced; MFN To Be Removed from Contracts BETHESDA, Md., September 6, 2016 – Northwest Biotherapeutics (NASDAQ: NWBO) (“NW Bio” or the “Company”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that Nasdaq has accepted NW Bio’s proposed remediation plan to resolve Nasdaq’s finding, previously disclosed by the Company, that NW Bio...
Read More
05
JUL
2016

NW Bio Announced a Registered Direct Offering of $3.7 Million With New Institutional Investors

Posted By :
Comments : Off
BETHESDA, Md., July 5, 2016 – Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has entered into definitive agreements with two new institutional investors for a registered direct offering with gross proceeds of $3.7 million. The Company will sell to the investors approximately 7.4 million shares of common stock at...
Read More